We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 07, 2021

Sabatolimab With or Without Spartalizumab in Advanced Solid Tumors

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Clin. Cancer Res 2021 Apr 21;[EPub Ahead of Print], G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, J Sarantopoulos, PL Bedard, CC Lin, FS Hodi, S Wilgenhof, A Santoro, CA Sabatos-Peyton, TA Longmire, A Xyrafas, H Sun, S Gutzwiller, L Manenti, A Naing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading